Wedbush Predicts Increased Earnings for TScan Therapeutics

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities researchers at Wedbush increased their FY2024 EPS estimates for TScan Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($1.09) for the year, up from their prior estimate of ($1.13). Wedbush currently has a “Outperform” rating and a $10.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share. Wedbush also issued estimates for TScan Therapeutics’ Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.96) EPS and FY2027 earnings at ($0.76) EPS.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.03. The firm had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%.

Other research analysts have also issued research reports about the company. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of TScan Therapeutics in a report on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research note on Friday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, TScan Therapeutics currently has a consensus rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Price Performance

TScan Therapeutics stock opened at $4.41 on Friday. The stock has a market cap of $233.62 million, a price-to-earnings ratio of -4.16 and a beta of 0.79. The company has a quick ratio of 7.77, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The business has a 50-day simple moving average of $5.31 and a 200 day simple moving average of $6.48. TScan Therapeutics has a 52 week low of $3.73 and a 52 week high of $9.69.

Institutional Investors Weigh In On TScan Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TCRX. Geode Capital Management LLC grew its position in TScan Therapeutics by 8.1% during the 3rd quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock worth $4,849,000 after acquiring an additional 72,967 shares during the last quarter. Barclays PLC increased its stake in shares of TScan Therapeutics by 341.1% in the third quarter. Barclays PLC now owns 58,067 shares of the company’s stock worth $289,000 after buying an additional 44,903 shares during the period. XTX Topco Ltd bought a new stake in TScan Therapeutics during the 3rd quarter valued at $112,000. Wellington Management Group LLP boosted its position in TScan Therapeutics by 38.9% during the 3rd quarter. Wellington Management Group LLP now owns 126,345 shares of the company’s stock valued at $629,000 after buying an additional 35,404 shares during the period. Finally, State Street Corp grew its holdings in TScan Therapeutics by 24.4% in the 3rd quarter. State Street Corp now owns 756,499 shares of the company’s stock worth $3,767,000 after acquiring an additional 148,414 shares during the last quarter. Institutional investors own 82.83% of the company’s stock.

Insider Activity

In other TScan Therapeutics news, insider Zoran Zdraveski sold 164,686 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total value of $951,885.08. Following the completion of the sale, the insider now directly owns 4,716 shares of the company’s stock, valued at $27,258.48. The trade was a 97.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Barbara Klencke purchased 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were acquired at an average price of $5.53 per share, with a total value of $27,650.00. Following the completion of the transaction, the director now owns 40,000 shares of the company’s stock, valued at approximately $221,200. This trade represents a 14.29 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have bought 15,000 shares of company stock worth $82,550. 2.76% of the stock is currently owned by insiders.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.